report-image

Biological Drugs Market Analysis By Source(Microbial, Mammalian), By Product(Monoclonal Antibodies (MABs), Vaccines, Hormones, Therapeutic Enzymes, Recombinant Proteins, Antisense, RNAi & Molecular Therapy, Blood Factors and Anticoagulants, Allergenic extracts, Human Cells and Tissues, Proteins, Gene Therapies, Cellular Therapies), By Disease(Oncology, Immunological Disorders, Cardiovascular Disorders, Haematological Disorders), By Manufacturing(Outsourced, In-house), By Route of Administration(Oral, Others (IV and IP)), By Drug Classification(Branded Drugs, Generic Drugs), By Mode of Purchase(Prescription Drugs, Over-The-Counter (OTC) Drugs), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Forecast 2024-2035

  • PUBLISHED ON
  • 9/1/2022
  • NO OF PAGES
  • 265
  • CATEGORY
  • Healthcare & Life Sciences

The global biological drugs market size was valued at USD 285.5 billion in 2021 and is projected to reach around USD 720.0 billion in 2030 exhibiting a CAGR of 10.0% in the forecasted period. The several government efforts, higher share of biologics in the market, and increasing use of biopharmaceuticals over chemically produced molecules are boosting the market growth. Moreover, rising geriatric population and growing interest in preventive healthcare are anticipated to augment market growth over the forecast period.

Demand for biological drugs is anticipated to attain grip in the coming future due to the global increase in elderly population and higher prevalence of chronic diseases. Moreover, the global biological market is helping from numerous healthcare awareness initiatives taken by both public and private organizations. Similarly, revolution in biomedical technology and constant R&D programs are expected to highlight further possibility for market growth. On the other hand, problems associated to patent expiry of popular drugs and costly nature of such drugs are estimated to constrain the complete market growth. Similarly, further threats of severe side effects and related risks from injectable biological drugs may also adversely influence the growth of the market.

Due to incidence of populations with high risk to the COVID-19 pandemic, officials are more eagerly manufacturing micro molecule medications to remain than in the past. The healthcare sector is employing strong plans to touch the goal, which entails enduring biological drugs and medicines manufacturing, hence reinforcement of the biologics manufacturing industry. Consequently, COVID-19 pandemic has brought strong growth towards the biological drugs market.

Source Insights

On the basis of the source used for the manufacturing of these biopharmaceuticals, they are segmented into microbial, mammalian, with an addition of some other sources including transgenic models, insect, avian, and transgenic animals.

Microbial expression systems recorded the largest revenue generation due to a significant number of drugs produced by using these products. Microbial expression systems usually cover Escherichia Coli and yeast.

Products developed using these expression systems include granulocyte-macrophage colony-stimulating factor, platelet-derived growth factor, recombinant insulin, and recombinant interferon. Johnson & Johnson, Novartis, and Genentech are the players implementing the usage of microbial systems.

Product Insights

Monoclonal antibodies (MABs) lead the market with the maximum revenue share owing to higher usage of this group of drugs in several therapeutic areas. MABs permit targeting of unnatural cells without damaging the healthy cells.

Furthermore, these drugs are mostly useful in cancer management, treatment of autoimmune diseases, comprising rheumatoid arthritis. Vaccines are predicted to witness the fastest growth in the coming years due to usage as a preventive tool in infectious diseases.

The increase of a virus-based therapeutic vaccine is in the process of growth for melanoma treatment. This is a genetically-modified product for in tumour cells and expresses a gene for an immune-stimulating protein.

DESCIMG1

Manufacturing Insights

Manufacturing is a part of the major stages of biologics production and includes of a substantial share of the biological drugs market. Mode of manufacturing is an essential aspect to be considered, as it characterizes the outsourcing and in-house activities of the sector.

Companies are electing to manufacture than to purchase an entity or outsource the services. This has managed to the larger share of in-house manufacturing for biologics biopharmaceutical manufacturing capacity. But, the price of the outsourcing contracts is moderately lower than for the overall market and would be incapable to drive sector growth as it does in the pharmaceutical market.

Disease Insights

Oncology has the largest share as a significance of the increasing incidence of cancer along with the presence of various R&D projects. These projects contain gene therapies and antisense. Corporations are involved in investing on own bioprocessing abilities. There are investments done by the CMOs for growing the commercial therapies for cancer eradication.

Additionally, oncology is predicted to maintain its governance over the forecasted period. Factors for the anticipated growth include the increasing adoption of products to decrease the series of severe events related with the usage of cancer chemotherapy.

 Region Insights

North America biological drugs market accounted for the largest share in 2021 due to the favourable reimbursement policies, presence of major companies, and high investment in R&D. Biological drugs accounts for about 38% of the total drug spending in the US. Approval of new biologic drugs is anticipated to further drive market growth during the forecasted period, for instance, in 2021, the U.S. FDA gave approval to 21 BLA’s. U.S market for biologics accounted for substantial share in 2021 due to increasing R&D spending for the biologic development combined with the presence of large number of FDA approved biologics in the nation.

The market in Europe, is predominantly driven by demand for biological drugs from the geriatric population of the region. As per the UN report, by 2025 geriatric population in Germany is anticipated to cover 33.2% of the total population in the nation.

In Asia, factors such as positive government initiatives and advanced funding for establishing new biotech companies, drug manufacturing facilities and life science organizations are predicted to stimulate the biological drugs market in the region. One of the important drivers responsible for the growth of the Chinese biological drugs market is continuous increase of biologic developing plants in the nation. For instance, in November 2021, WuXi Biologics launched the GMP operations at it drug production facility in China. The 12,000 m2 plant will manufacture approximately 60 million vials for commercial drug annually.

Key Companies Insights

Key players are aiming on their technological partnerships, collaborations, and merger & acquisitions policies to gain a competitive edge and expand their product portfolio & business footmark. The ongoing COVID-19 pandemic hindered the healthcare systems worldwide and driven market players to update products for unexploited prospects.

Some of the key players operating in the global biological drugs market include:

·         Eli Lilly & Company

·         Samsung Biologics

·         F Hoffman La Roche

·         Celltrion Addgene

·         Bristol-Myers Squibb Company

·         Amgen Inc.

·         GlaxoSmithKline plc.

·         Abbvie Inc.

·         Baxter

·         Sanofi

·         Pfizer Inc.

·         Merck & Co. Inc.

·         Biocon Biologics

·         Moderna Inc.

·         Novo Nordisk A/S

·         Other players

Some of the Recent Developments:

·         In August 2021, Moderna Inc. completed the rolling application process to the FDA for full licensing of the Moderna COVID-19 vaccine for active vaccination to prevent COVID-19 in people aged 18 and higher.

·         In August 2021, Pfizer Inc. and BioNTech SE have started a supplemental Biologics License Application with the FDA to get sanction for a booster dosage of COMIRNATY to prevent COVID-19 in patients aged 16 and up.

·         Biocon Biologics is in discussions with ADQ, the Abu Dhabi government's wealth fund, to improve the financing as India's largest biosimilar maker increases its production to generate value for stakeholders ahead of a projected IPO.

Segments

By Source

·         Microbial

·         Mammalian

·         Others

By Product

·         Monoclonal Antibodies (MABs)

·         Vaccines

·         Hormones

·         Therapeutic Enzymes

·         Recombinant Proteins

·         Antisense, RNAi & Molecular Therapy

·         Blood Factors and Anticoagulants

·         Allergenic extracts

·         Human Cells and Tissues

·         Proteins

·         Gene Therapies

·         Cellular Therapies

·         Others

By Disease

·         Oncology

·         Immunological Disorders

·         Cardiovascular Disorders

·         Haematological Disorders

·         Others

By Manufacturing

·         Outsourced

·         In-house

By Route of Administration

·         Oral

·         Others (IV and IP)

By Drug Classification

·         Branded Drugs

·         Generic Drugs

By Mode of Purchase

·         Prescription Drugs

·         Over-The-Counter (OTC) Drugs

By Distribution Channel

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

By Geography

·         North America

o   U.S.

o   Canada

o   Mexico

·         Europe

o   U.K.

o   Germany

o   France

o   Italy

o   Spain

o   Russia

·         Asia-Pacific

o   Japan

o   China

o   India

o   Australia

o   South Korea

o   ASEAN

·         Latin America

o   Brazil

o   Argentina

o   Colombia

·         MEA

o   South Africa

o   Saudi Arabia

o   UAE

o   Egypt

Key Points:
Define, describe and forecast Biological Drugs product market by type, application, end user and region.
Provide enterprise external environment analysis and PEST analysis.
Provide strategies for company to deal with the impact of COVID-19.
Provide market dynamic analysis, including market driving factors, market development constraints.
Provide market entry strategy analysis for new players or players who are ready to enter the market, including market segment definition, client analysis, distribution model, product messaging and positioning, and price strategy analysis.
Keep up with international market trends and provide analysis of the impact of the COVID-19 epidemic on major regions of the world.
Analyze the market opportunities of stakeholders and provide market leaders with details of the competitive landscape.
Base Year: 2023
Historic Year: 2016-2022
Forecast: 2024-2035


1 Biological Drugs Market Definition and Overview
1.1 Objectives of the Study
1.2 Overview of Biological Drugs
1.3 Biological Drugs Market Scope and Market Size Estimation
1.4 Market Segmentation
1.4.1 Types of Biological Drugs
1.4.2 Applications of Biological Drugs
1.5 Market Exchange Rate

2 Research Method and Logic
2.1 Methodology
2.2 Research Data Source

3 Market Competition Analysis
3.1 Eli Lilly and Company. Market Performance Analysis
3.1.1 Eli Lilly and Company. Basic Information
3.1.2 Product and Service Analysis
3.1.3 Strategies for Company to Deal with the Impact of COVID-19
3.1.4 Eli Lilly and Company. Sales, Value, Price, Gross Margin 2016-2021
3.2 Baxter International Inc. Market Performance Analysis
3.2.1 Baxter International Inc. Basic Information
3.2.2 Product and Service Analysis
3.2.3 Strategies for Company to Deal with the Impact of COVID-19
3.2.4 Baxter International Inc. Sales, Value, Price, Gross Margin 2016-2021
3.3 Biogen Idec. Market Performance Analysis
3.3.1 Biogen Idec. Basic Information
3.3.2 Product and Service Analysis
3.3.3 Strategies for Company to Deal with the Impact of COVID-19
3.3.4 Biogen Idec. Sales, Value, Price, Gross Margin 2016-2021
3.4 Novartis AG. Market Performance Analysis
3.4.1 Novartis AG. Basic Information
3.4.2 Product and Service Analysis
3.4.3 Strategies for Company to Deal with the Impact of COVID-19
3.4.4 Novartis AG. Sales, Value, Price, Gross Margin 2016-2021
3.5 Pfizer Inc. Market Performance Analysis
3.5.1 Pfizer Inc. Basic Information
3.5.2 Product and Service Analysis
3.5.3 Strategies for Company to Deal with the Impact of COVID-19
3.5.4 Pfizer Inc. Sales, Value, Price, Gross Margin 2016-2021
3.6 GlaxoSmithKline plc. Market Performance Analysis
3.6.1 GlaxoSmithKline plc. Basic Information
3.6.2 Product and Service Analysis
3.6.3 Strategies for Company to Deal with the Impact of COVID-19
3.6.4 GlaxoSmithKline plc. Sales, Value, Price, Gross Margin 2016-2021
3.7 Amgen Inc. Market Performance Analysis
3.7.1 Amgen Inc. Basic Information
3.7.2 Product and Service Analysis
3.7.3 Strategies for Company to Deal with the Impact of COVID-19
3.7.4 Amgen Inc. Sales, Value, Price, Gross Margin 2016-2021
3.8 Bristol-Myers Squibb Company. Market Performance Analysis
3.8.1 Bristol-Myers Squibb Company. Basic Information
3.8.2 Product and Service Analysis
3.8.3 Strategies for Company to Deal with the Impact of COVID-19
3.8.4 Bristol-Myers Squibb Company. Sales, Value, Price, Gross Margin 2016-2021
3.9 Merck & Co., Inc. Market Performance Analysis
3.9.1 Merck & Co., Inc. Basic Information
3.9.2 Product and Service Analysis
3.9.3 Strategies for Company to Deal with the Impact of COVID-19
3.9.4 Merck & Co., Inc. Sales, Value, Price, Gross Margin 2016-2021
3.10 Abbott Laboratories. Market Performance Analysis
3.10.1 Abbott Laboratories. Basic Information
3.10.2 Product and Service Analysis
3.10.3 Strategies for Company to Deal with the Impact of COVID-19
3.10.4 Abbott Laboratories. Sales, Value, Price, Gross Margin 2016-2021

4 Market Segment by Type, Historical Data and Market Forecasts
4.1 Global Biological Drugs Production and Value by Type
4.1.1 Global Biological Drugs Production by Type 2016-2021
4.1.2 Global Biological Drugs Market Value by Type 2016-2021
4.2 Global Biological Drugs Market Production, Value and Growth Rate by Type 2016-2021
4.2.1 Gardasil Market Production, Value and Growth Rate
4.2.2 Prenvar 13 Market Production, Value and Growth Rate
4.2.3 Fluzone Market Production, Value and Growth Rate
4.2.4 Cervarix Market Production, Value and Growth Rate
4.2.5 Varivax Market Production, Value and Growth Rate
4.3 Global Biological Drugs Production and Value Forecast by Type
4.3.1 Global Biological Drugs Production Forecast by Type 2021-2026
4.3.2 Global Biological Drugs Market Value Forecast by Type 2021-2026
4.4 Global Biological Drugs Market Production, Value and Growth Rate by Type Forecast 2021-2026
4.4.1 Gardasil Market Production, Value and Growth Rate Forecast
4.4.2 Prenvar 13 Market Production, Value and Growth Rate Forecast
4.4.3 Fluzone Market Production, Value and Growth Rate Forecast
4.4.4 Cervarix Market Production, Value and Growth Rate Forecast
4.4.5 Varivax Market Production, Value and Growth Rate Forecast

5 Market Segment by Application, Historical Data and Market Forecasts
5.1 Global Biological Drugs Consumption and Value by Application
5.1.1 Global Biological Drugs Consumption by Application 2016-2021
5.1.2 Global Biological Drugs Market Value by Application 2016-2021
5.2 Global Biological Drugs Market Consumption, Value and Growth Rate by Application 2016-2021
5.2.1 Hospital Market Consumption, Value and Growth Rate
5.2.2 Research Center Market Consumption, Value and Growth Rate
5.3 Global Biological Drugs Consumption and Value Forecast by Application
5.3.1 Global Biological Drugs Consumption Forecast by Application 2021-2026
5.3.2 Global Biological Drugs Market Value Forecast by Application 2021-2026
5.4 Global Biological Drugs Market Consumption, Value and Growth Rate by Application Forecast 2021-2026
5.4.1 Hospital Market Consumption, Value and Growth Rate Forecast
5.4.2 Research Center Market Consumption, Value and Growth Rate Forecast

6 Global Biological Drugs by Region, Historical Data and Market Forecasts
6.1 Global Biological Drugs Sales by Region 2016-2021
6.2 Global Biological Drugs Market Value by Region 2016-2021
6.3 Global Biological Drugs Market Sales, Value and Growth Rate by Region 2016-2021
6.3.1 North America
6.3.2 Europe
6.3.3 Asia Pacific
6.3.4 South America
6.3.5 Middle East and Africa
6.4 Global Biological Drugs Sales Forecast by Region 2021-2026
6.5 Global Biological Drugs Market Value Forecast by Region 2021-2026
6.6 Global Biological Drugs Market Sales, Value and Growth Rate Forecast by Region 2021-2026
6.6.1 North America
6.6.2 Europe
6.6.3 Asia Pacific
6.6.4 South America
6.6.5 Middle East and Africa

7 United State Market Size Analysis 2016-2026
7.1 United State Biological Drugs Value and Market Growth 2016-2021
7.2 United State Biological Drugs Sales and Market Growth 2016-2021
7.3 United State Biological Drugs Market Value Forecast 2021-2026

8 Canada Market Size Analysis 2016-2026
8.1 Canada Biological Drugs Value and Market Growth 2016-2021
8.2 Canada Biological Drugs Sales and Market Growth 2016-2021
8.3 Canada Biological Drugs Market Value Forecast 2021-2026

9 Germany Market Size Analysis 2016-2026
9.1 Germany Biological Drugs Value and Market Growth 2016-2021
9.2 Germany Biological Drugs Sales and Market Growth 2016-2021
9.3 Germany Biological Drugs Market Value Forecast 2021-2026

10 UK Market Size Analysis 2016-2026
10.1 UK Biological Drugs Value and Market Growth 2016-2021
10.2 UK Biological Drugs Sales and Market Growth 2016-2021
10.3 UK Biological Drugs Market Value Forecast 2021-2026

11 France Market Size Analysis 2016-2026
11.1 France Biological Drugs Value and Market Growth 2016-2021
11.2 France Biological Drugs Sales and Market Growth 2016-2021
11.3 France Biological Drugs Market Value Forecast 2021-2026

12 Italy Market Size Analysis 2016-2026
12.1 Italy Biological Drugs Value and Market Growth 2016-2021
12.2 Italy Biological Drugs Sales and Market Growth 2016-2021
12.3 Italy Biological Drugs Market Value Forecast 2021-2026

13 Spain Market Size Analysis 2016-2026
13.1 Spain Biological Drugs Value and Market Growth 2016-2021
13.2 Spain Biological Drugs Sales and Market Growth 2016-2021
13.3 Spain Biological Drugs Market Value Forecast 2021-2026

14 Russia Market Size Analysis 2016-2026
14.1 Russia Biological Drugs Value and Market Growth 2016-2021
14.2 Russia Biological Drugs Sales and Market Growth 2016-2021
14.3 Russia Biological Drugs Market Value Forecast 2021-2026

15 China Market Size Analysis 2016-2026
15.1 China Biological Drugs Value and Market Growth 2016-2021
15.2 China Biological Drugs Sales and Market Growth 2016-2021
15.3 China Biological Drugs Market Value Forecast 2021-2026

16 Japan Market Size Analysis 2016-2026
16.1 Japan Biological Drugs Value and Market Growth 2016-2021
16.2 Japan Biological Drugs Sales and Market Growth 2016-2021
16.3 Japan Biological Drugs Market Value Forecast 2021-2026

17 South Korea Market Size Analysis 2016-2026
17.1 South Korea Biological Drugs Value and Market Growth 2016-2021
17.2 South Korea Biological Drugs Sales and Market Growth 2016-2021
17.3 South Korea Biological Drugs Market Value Forecast 2021-2026

18 Australia Market Size Analysis 2016-2026
18.1 Australia Biological Drugs Value and Market Growth 2016-2021
18.2 Australia Biological Drugs Sales and Market Growth 2016-2021
18.3 Australia Biological Drugs Market Value Forecast 2021-2026

19 Thailand Market Size Analysis 2016-2026
19.1 Thailand Biological Drugs Value and Market Growth 2016-2021
19.2 Thailand Biological Drugs Sales and Market Growth 2016-2021
19.3 Thailand Biological Drugs Market Value Forecast 2021-2026

20 Brazil Market Size Analysis 2016-2026
20.1 Brazil Biological Drugs Value and Market Growth 2016-2021
20.2 Brazil Biological Drugs Sales and Market Growth 2016-2021
20.3 Brazil Biological Drugs Market Value Forecast 2021-2026

21 Argentina Market Size Analysis 2016-2026
21.1 Argentina Biological Drugs Value and Market Growth 2016-2021
21.2 Argentina Biological Drugs Sales and Market Growth 2016-2021
21.3 Argentina Biological Drugs Market Value Forecast 2021-2026

22 Chile Market Size Analysis 2016-2026
22.1 Chile Biological Drugs Value and Market Growth 2016-2021
22.2 Chile Biological Drugs Sales and Market Growth 2016-2021
22.3 Chile Biological Drugs Market Value Forecast 2021-2026

23 South Africa Market Size Analysis 2016-2026
23.1 South Africa Biological Drugs Value and Market Growth 2016-2021
23.2 South Africa Biological Drugs Sales and Market Growth 2016-2021
23.3 South Africa Biological Drugs Market Value Forecast 2021-2026

24 Egypt Market Size Analysis 2016-2026
24.1 Egypt Biological Drugs Value and Market Growth 2016-2021
24.2 Egypt Biological Drugs Sales and Market Growth 2016-2021
24.3 Egypt Biological Drugs Market Value Forecast 2021-2026

25 UAE Market Size Analysis 2016-2026
25.1 UAE Biological Drugs Value and Market Growth 2016-2021
25.2 UAE Biological Drugs Sales and Market Growth 2016-2021
25.3 UAE Biological Drugs Market Value Forecast 2021-2026

26 Saudi Arabia Market Size Analysis 2016-2026
26.1 Saudi Arabia Biological Drugs Value and Market Growth 2016-2021
26.2 Saudi Arabia Biological Drugs Sales and Market Growth 2016-2021
26.3 Saudi Arabia Biological Drugs Market Value Forecast 2021-2026

27 Market Dynamic Analysis and Development Suggestions
27.1 Market Drivers
27.2 Market Development Constraints
27.3 PEST Analysis
27.3.1 Political Factors
27.3.2 Economic Factors
27.3.3 Social Factors
27.3.4 Technological Factors
27.4 Industry Trends Under COVID-19
27.4.1 Risk Assessment on COVID-19
27.4.2 Assessment of the Overall Impact of COVID-19 on the Industry
27.4.3 Pre COVID-19 and Post COVID-19 Market Scenario
27.5 Market Entry Strategy Analysis
27.5.1 Market Definition
27.5.2 Client
27.5.3 Distribution Model
27.5.4 Product Messaging and Positioning
27.5.5 Price
27.6 Advice on Entering the Market

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process




We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.


Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.


CHOOSE LICENSE TYPE
QLOUD
Pricing

Select a license type that suits your business needs

Single User Access

US $3950

Only Three Thousand Nine Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $4950

Only Four Thousand Nine Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $5950

Only Five Thousand Nine Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI